Search results
Results: 32
Number of items: 32
-
van Kempen, Z. L. E., Wieske, L., Stalman, E. W., Kummer, L. Y. L., van Dam, P. J., Volkers, A. G., Boekel, L., Toorop, A. A., Strijbis, E. M. M., Tas, S. W., Wolbink, G. J., Löwenberg, M., van Sandt, C., ten Brinke, A., Verstegen, N. J. M., Steenhuis, M., Kuijpers, T. W., van Ham, S. M., Rispens, T., ... T2B! immunity against SARS-CoV-2 study group (2022). Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate? Multiple sclerosis and related disorders, 57, Article 103416. https://doi.org/10.1016/j.msard.2021.103416 -
Palomares Cabeza, V., Kummer, L. Y. L., Wieske, L., Hagen, R. R., Duurland, M., Konijn, V. A. L., van Dam, K. P. J., Stalman, E. W., van de Sandt, C. E., Boekel, L., Verstegen, N. J. M., Steenhuis, M., Rispens, T., Tas, S. W., Wolbink, G., Killestein, J., Kuijpers, T. W., van Ham, S. M., Eftimov, F., ... Target-to-B! (T2B!) SARS-CoV-2 study group (2022). Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod. Neurology® Neuroimmunology & Neuroinflammation, 9(4), Article e1178. https://doi.org/10.1212/NXI.0000000000001178 -
Wieske, L., Takkenberg, R. B., Tas, S. W., Bemelman, F. J., ten Brinke, A., Verstegen, N. J. M., van Ham, S. M., & T2B! immunity against SARS-CoV-2 study group (2022). Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases. BMC Medicine, 20, Article 100. https://doi.org/10.1186/s12916-022-02310-7 -
Boekel, L., Steenhuis, M., Hooijberg, F., Besten, Y. R., van Kempen, Z. L. E., Kummer, L. Y., van Dam, K. P. J., Stalman, E. W., Vogelzang, E. H., Cristianawati, O., Keijzer, S., Vidarsson, G., Voskuyl, A. E., Wieske, L., Eftimov, F., van Vollenhoven, R., Kuijpers, T. W., van Ham, S. M., Tas, S. W., ... Wolbink, G. (2021). Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. The Lancet. Rheumatology, 3(11), e778-e788. https://doi.org/10.1016/S2665-9913(21)00222-8
-
Boekel, L., Hooijberg, F., van Kempen, Z. L. E., Vogelzang, E. H., Tas, S. W., Killestein, J., Nurmohamed, M. T., Boers, M., Kuijpers, T. W., van Ham, S. M., Eftimov, F., Wieske, L., Rispens, T., & Wolbink, G. J. (2021). Perspective of patients with autoimmune diseases on COVID-19 vaccination. The Lancet. Rheumatology, 3(4), e241-e243. https://doi.org/10.1016/S2665-9913(21)00037-0
Page 3 of 4